Health Economics

In addition to requirements for ColoGenix™ Pre-View to be easy to use, and accurate, it is also important that its implementation in a care pathway makes sound economic sense. Health economics have been at the forefront of our considerations since the early development phases of all our products. Due to the unique scientific and logistical systems that we have integrated into our products, we are able to keep both hardware and sample processing costs relatively low.

ScHARR (School of Health and Related Research) based at the University of Sheffield conducted a fully independent and thorough evaluation on our ColoGenix™ Pre-View product.

The final report suggests that the ColoGenix™ Pre-View really is the test that health economists have been waiting for. A copy of the ScHARR report can be downloaded below, or from the downloads section of the website.

‘A report undertaken by the School of Health and Related Research (ScHARR) estimated that a net monetary benefit in the region of £200 per person if the potential to reduce colonoscopies for suspected colorectal cancer by 60% is realised.’
Summary extract from the ScHAAR health economic study – September 2008
To download the full report please Click Here